Impaired oligodendroglial turnover is associated with myelin pathology in focal cortical dysplasia and tuberous sclerosis complex

Conventional antiepileptic drugs suppress the excessive firing of neurons during seizures. In drug‐resistant patients, treatment failure indicates an alternative important epileptogenic trigger. Two epilepsy‐associated pathologies show myelin deficiencies in seizure‐related brain regions: Focal Cortical Dysplasia IIB (FCD) and cortical tubers in Tuberous Sclerosis Complex (TSC). Studies uncovering white matter‐pathology mechanisms are therefore urgently needed to gain more insight into epileptogenesis, the propensity to maintain seizures, and their associated comorbidities such as cognitive defects. We analyzed epilepsy surgery specimens of FCD IIB (n = 22), TSC (n = 8), and other malformations of cortical development MCD (n = 12), and compared them to autopsy and biopsy cases (n = 15). The entire lesional pathology was assessed using digital immunohistochemistry, immunofluorescence and western blotting for oligodendroglial lineage, myelin and mTOR markers, and findings were correlated to clinical parameters. White matter pathology with depleted myelin and oligodendroglia were found in 50% of FCD IIB and 62% of TSC cases. Other MCDs had either a normal content or even showed reactive oligodendrolial hyperplasia. Furthermore, myelin deficiency was associated with increased mTOR expression and the lower amount of oligodendroglia was linked with their precursor cells (PDGFRa). The relative duration of epilepsy (normalized to age) also correlated positively to mTOR activation and negatively to myelination. Decreased content of oligodendroglia and missing precursor cells indicated insufficient oligodendroglial development, probably mediated by mTOR, which may ultimately lead to severe myelin loss. In terms of disease management, an early and targeted treatment could restore normal myelin development and, therefore, alter seizure threshold and improve cognitive outcome.

[1]  F. Woermann,et al.  Mild Malformation of Cortical Development with Oligodendroglial Hyperplasia in Frontal Lobe Epilepsy: A New Clinico‐Pathological Entity , 2017, Brain pathology.

[2]  Sharyl L Fyffe-Maricich,et al.  Intracellular signaling pathway regulation of myelination and remyelination in the CNS , 2016, Experimental Neurology.

[3]  Pavel Krsek,et al.  Novel Histopathological Patterns in Cortical Tubers of Epilepsy Surgery Patients with Tuberous Sclerosis Complex , 2016, PloS one.

[4]  S. Baulac,et al.  Genetic models of focal epilepsies , 2016, Journal of Neuroscience Methods.

[5]  J. Zentner,et al.  Whole Transcriptome Screening Reveals Myelination Deficits in Dysplastic Human Temporal Neocortex , 2016, Cerebral cortex.

[6]  Nadia Colombo,et al.  Type II focal cortical dysplasia: Ex vivo 7T magnetic resonance imaging abnormalities and histopathological comparisons , 2016, Annals of neurology.

[7]  Ling Lin,et al.  Mosaic and Intronic Mutations in TSC1/TSC2 Explain the Majority of TSC Patients with No Mutation Identified by Conventional Testing , 2015, PLoS genetics.

[8]  C. Batt,et al.  Apoptosis of Oligodendrocytes during Early Development Delays Myelination and Impairs Subsequent Responses to Demyelination , 2015, The Journal of Neuroscience.

[9]  H. Kitaura,et al.  Somatic Mutations in the MTOR gene cause focal cortical dysplasia type IIb , 2015, Annals of neurology.

[10]  P. Lockhart,et al.  Familial cortical dysplasia caused by mutation in the mammalian target of rapamycin regulator NPRL3 , 2015, Annals of neurology.

[11]  Joseph B Hiatt,et al.  PI3K/AKT pathway mutations cause a spectrum of brain malformations from megalencephaly to focal cortical dysplasia. , 2015, Brain : a journal of neurology.

[12]  Beth K. Martin,et al.  Mammalian target of rapamycin pathway mutations cause hemimegalencephaly and focal cortical dysplasia , 2015, Annals of neurology.

[13]  Seok-Gu Kang,et al.  Brain somatic mutations in MTOR cause focal cortical dysplasia type II leading to intractable epilepsy , 2015, Nature Medicine.

[14]  K. Davis,et al.  Myelination, oligodendrocytes, and serious mental illness , 2014, Glia.

[15]  S. Amor,et al.  Oligodendrocyte‐microglia cross‐talk in the central nervous system , 2014, Immunology.

[16]  M. Tripathi,et al.  Epileptogenic networks and drug-resistant epilepsy: Present and future perspectives of epilepsy research-Utility for the epileptologist and the epilepsy surgeon , 2014, Annals of Indian Academy of Neurology.

[17]  M. Duchowny,et al.  Predictors of seizure‐free outcome after epilepsy surgery for pediatric tuberous sclerosis complex , 2013, Epilepsia.

[18]  F. Gage,et al.  A regenerative approach to the treatment of multiple sclerosis , 2013, Nature.

[19]  Benoit Scherrer,et al.  Diffusion tensor imaging and related techniques in tuberous sclerosis complex: review and future directions. , 2013, Future neurology.

[20]  E. Hogan,et al.  Myelin Recovery in Multiple Sclerosis: The Challenge of Remyelination , 2013, Brain sciences.

[21]  L. Martinian,et al.  A quantitative study of white matter hypomyelination and oligodendroglial maturation in focal cortical dysplasia type II , 2013, Epilepsia.

[22]  T. Wood,et al.  mTOR: a link from the extracellular milieu to transcriptional regulation of oligodendrocyte development , 2013, ASN neuro.

[23]  E. Pataraia,et al.  Prominent oligodendroglial response in surgical specimens of patients with temporal lobe epilepsy. , 2012, Clinical neuropathology.

[24]  M. Rosenblum,et al.  Disseminated oligodendroglial-like leptomeningeal tumor of childhood: a distinctive clinicopathologic entity , 2012, Acta Neuropathologica.

[25]  Rita Garbelli,et al.  Blurring in patients with temporal lobe epilepsy: clinical, high-field imaging and ultrastructural study. , 2012, Brain : a journal of neurology.

[26]  I. Pirko,et al.  Biogenesis and Significance of Central Nervous System Myelin , 2012, Seminars in Neurology.

[27]  I. Blümcke,et al.  Neuropathologic measurements in focal cortical dysplasias: validation of the ILAE 2011 classification system and diagnostic implications for MRI , 2012, Acta Neuropathologica.

[28]  Robert P. Carson,et al.  Neuronal and glia abnormalities in Tsc1-deficient forebrain and partial rescue by rapamycin , 2012, Neurobiology of Disease.

[29]  S. Uppin,et al.  Meningiomas: correlation of Ki67 with histological grade. , 2011, Neurology India.

[30]  Maria Thom,et al.  The clinicopathologic spectrum of focal cortical dysplasias: A consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission 1 , 2011, Epilepsia.

[31]  S. Goldman,et al.  Defective Glial Maturation in Vanishing White Matter Disease , 2011, Journal of neuropathology and experimental neurology.

[32]  W. Richardson,et al.  NG2 Glia Generate New Oligodendrocytes But Few Astrocytes in a Murine Experimental Autoimmune Encephalomyelitis Model of Demyelinating Disease , 2010, The Journal of Neuroscience.

[33]  H. Budka,et al.  Tubulin polymerization promoting protein (TPPP/p25) as a marker for oligodendroglial changes in multiple sclerosis , 2010, Glia.

[34]  E. Widjaja,et al.  Diffusion Tensor Imaging of Commissural and Projection White Matter in Tuberous Sclerosis Complex and Correlation with Tuber Load , 2010, American Journal of Neuroradiology.

[35]  G. Mathern,et al.  Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies , 2009, Epilepsia.

[36]  D. McTigue,et al.  The life, death, and replacement of oligodendrocytes in the adult CNS , 2008, Journal of neurochemistry.

[37]  G. Mathern,et al.  Defining the spectrum of international practice in pediatric epilepsy surgery patients (Epilepsia (2008) 49, 1, (146-155)) , 2008 .

[38]  J Helen Cross,et al.  Defining the spectrum of international practice in pediatric epilepsy surgery patients , 2008, Epilepsia.

[39]  C. Elger,et al.  Differential Pi3K‐pathway Activation in Cortical Tubers and Focal Cortical Dysplasias with Balloon Cells , 2007, Brain pathology.

[40]  D. Hartline,et al.  Rapid Conduction and the Evolution of Giant Axons and Myelinated Fibers , 2007, Current Biology.

[41]  C. Elger,et al.  Activation of Akt independent of PTEN and CTMP tumor-suppressor gene mutations in epilepsy-associated Taylor-type focal cortical dysplasias , 2006, Acta Neuropathologica.

[42]  D. Kwiatkowski,et al.  Tuberous Sclerosis: from Tubers to mTOR , 2003, Annals of human genetics.

[43]  Horst Urbach,et al.  Focal Cortical Dysplasia of Taylor's Balloon Cell Type: A Clinicopathological Entity with Characteristic Neuroimaging and Histopathological Features, and Favorable Postsurgical Outcome , 2002, Epilepsia.

[44]  Su-Chun Zhang.  Defining glial cells during CNS development , 2001, Nature Reviews Neuroscience.

[45]  Kortaro Tanaka,et al.  Activation of NG2-positive oligodendrocyte progenitor cells during post-ischemic reperfusion in the rat brain , 2001, Neuroreport.

[46]  W T Blume,et al.  Proposal for a New Classification of Outcome with Respect to Epileptic Seizures Following Epilepsy Surgery , 2001, Epilepsia.

[47]  H. Lüders,et al.  Proposal for a New Classification of Outcome with Respect to Epileptic Seizures Following Epilepsy Surgery , 2001 .

[48]  S. Sisodiya.  Surgery for malformations of cortical development causing epilepsy. , 2000, Brain : a journal of neurology.

[49]  Christopher N Martyn,et al.  Prevalence of tuberous sclerosis estimated by capture-recapture analysis , 1998, The Lancet.

[50]  M. Schachner,et al.  Monoclonal antibodies (O1 to O4) to oligodendrocyte cell surfaces: an immunocytological study in the central nervous system. , 1981, Developmental biology.

[51]  D. Kwiatkowski,et al.  Tuberous sclerosis. , 1994, Archives of dermatology.